Phase II trial: efficacy and toxicity of induction pemetrexed (Alimta) and oxaliplatin (Eloxatin) in patients with locally advanced head and neck squamous cell carcinoma.

Trial Profile

Phase II trial: efficacy and toxicity of induction pemetrexed (Alimta) and oxaliplatin (Eloxatin) in patients with locally advanced head and neck squamous cell carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2012

At a glance

  • Drugs Oxaliplatin (Primary) ; Pemetrexed (Primary)
  • Indications Head and neck cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 09 Mar 2012 Actual patient number 42 added as reported by ClinicalTrials.gov.
    • 09 Mar 2012 Actual end date Jun 2010 added as reported by ClinicalTrials.gov.
    • 09 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top